Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers Get access Arrow Jul 10, 2025 | Lymphopenia
Reverse Translation Identifies the Synergistic Role of Immune Checkpoint Blockade and IL15 to Enhance Immunotherapy of Ovarian Cancer Mar 27, 2025 | Ovarian Cancer
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors Aug 5, 2024 | Non-Hodgkin Lymphoma
Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. Aug 5, 2024 | Non-Hodgkin Lymphoma
